Zoetis Conducts First-Ever Annual Meeting of Shareholders

Business Wire
Zoetis Conducts First-Ever Annual Meeting of Shareholders
.

View photo

Zoetis CEO Juan Ramon Alaix speaking at the 2014 Annual Meeting of Shareholders. Multimedia Gallery …

FLORHAM PARK, N.J.--(BUSINESS WIRE)--

Zoetis Inc. (ZTS) marked another milestone in the company’s launch as an independent public company today, conducting its first-ever Annual Meeting of Shareholders. The company, which became fully independent in June 2013 after completing its separation from Pfizer, hosted the event this morning at the Hilton Short Hills Hotel, in Short Hills, New Jersey.

Zoetis Chairman Michael McCallister presided over the business portion of the meeting and shareholder voting. He was joined by Zoetis Chief Executive Officer Juan Ramón Alaix who discussed the company’s first year as an independent company, the core strengths of its business model, and its long-term value proposition for shareholders.

A full replay of the meeting is available at http://investor.zoetis.com/events-presentations, along with a copy of Mr. Alaix’s prepared remarks and presentation.

Preliminary results from the Annual Meeting of Shareholders indicate the following results of shareholder voting:

  • Gregory Norden, Louise M. Parent and Robert W. Scully have been elected as directors for three-year terms.
  • Shareholders ratified and approved the selection of KPMG LLP as the company’s independent registered public accounting firm for the 2014 fiscal year.
  • Shareholders voted to approve, on an advisory basis, the compensation of the company’s named executive officers, and to approve the holding of an advisory vote on executive compensation every year. In addition, shareholders voted to approve the company’s 2013 Equity and Incentive Plan.

The final results of the shareholder voting are subject to verification by the independent election inspectors and will be filed in a Form 8-K and available on the company’s website.

About Zoetis

Zoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. In 2013, the company generated annual revenue of $4.6 billion. With approximately 9,800 employees worldwide at the beginning of 2014, Zoetis has a local presence in approximately 70 countries, including 28 manufacturing facilities in 11 countries. Its products serve veterinarians, livestock producers and people who raise and care for farm and companion animals in 120 countries. For more information, visit www.zoetis.com.

DISCLOSURE NOTICES

Forward-Looking Statements: This press release contains forward-looking statements, which reflect the current views of Zoetis with respect to business plans or prospects, future operating or financial performance, expectations regarding products, future use of cash and dividend payments, and other future events. These statements are not guarantees of future performance or actions. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management's underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Zoetis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2013, including in the sections thereof captioned “Forward-Looking Information and Factors That May Affect Future Results” and “Item 1A. Risk Factors,” in our Quarterly Reports on Form 10-Q and in our Current Reports on Form 8-K. These filings and subsequent filings are available online at www.sec.gov, www.zoetis.com, or on request from Zoetis.

Internet Posting of Information: We routinely post information that may be important to investors in the 'Investors' section of our web site at www.zoetis.com, on our Facebook page at http://www.facebook.com/zoetis and on Twitter @zoetis. We encourage investors and potential investors to consult our website regularly and to follow us on Facebook and Twitter for important information about us.

MULTIMEDIA AVAILABLE:http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50864747&lang=en

Contact:
Zoetis Inc.
Media :
Bill Price, 1-973-443-2742 (o)
william.price@zoetis.com
or
Elinore White, 1-973-443-2835 (o)
elinore.y.white@zoetis.com
or
Investors :
John O'Connor, 1-973-822-7088 (o)

Rates

View Comments (0)